Boston Scientific Corp.’s Ingenio and Advantio pacemakers won U.S. approval to treat abnormally slow heartbeats, clearing the way for sales of devices that have been in development for a decade in the $4 billion global market.
Boston Scientific Corp.’s Cognis and Teligen defibrillators, used to shock hearts into a normal rhythm, may have a flaw that’s has been linked to a death, said Rick Wise, an analyst with Leerink Swann & Co.
Hospira Inc., embroiled in regulatory scrutiny for flaws in its manufacturing practices, has become so cheap that buyers may now pounce to claim a third of the world’s market for specialty generic injectable drugs.
Johnson & Johnson fell the most in six weeks in New York trading after the company, the world’s largest maker of health products, lowered its full-year earnings forecast because of a series of over-the-counter drug recalls.
Johnson & Johnson, the world’s biggest health-products company, reported a 29 percent increase in first-quarter profit, boosted by a gain from litigation and higher sales of surgical tools and Listerine mouth wash.
Johnson & Johnson’s newfound dominance of the orthopedic-device market, cemented by its $21.3 billion acquisition of Synthes Inc. , may drive rivals Zimmer Holdings Inc. and Stryker Corp. to seek purchases of their own.